Patents Examined by Jeanine A. Goldberg
  • Patent number: 10280460
    Abstract: The present invention relates to a DNA sequence showing difference between the female and male individuals of Litopenaeus vannamei and its corresponding acquired method. The method comprises: respectively conducting high-through put sequencing on the mixing pools of female individuals and male individuals in by high-through put sequencing platform; conducting bioinformatic analysis on the sequencing results to screen out sequences showing significant difference between the mixing pools of female and male individuals; verifying the obtained sex difference sequence in individuals from different sources; and finally, obtaining a probe sequence for female and male identification of L. vannamei, so that the genetic sex of this species can be accurately identified using the sequences. The method of the present invention has the characteristics of high efficiency, accuracy and reliability, and possess broad application potential in the early sex identification and sex control research of prawns.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: May 7, 2019
    Inventors: Jianhai Xiang, Yang Yu, Fuhua Li, Xiaojun Zhang
  • Patent number: 10266900
    Abstract: The present invention relates to the novel use of syndecan-2 (SDC2) gene as a CpG methylation biomarker for detecting precancerous lesions, and more particularly, to the use of the SDC2 gene as a biomarker to early diagnose colorectal precancerous lesions by measuring the degree of methylation of the SDC2 gene. The present invention provides a method of providing information for diagnosis of precancerous lesions by detecting methylation of the CpG islands of the SDC2 gene. In addition, the use of the methylation detection and kit according to the present invention makes it possible to diagnose colorectal precancerous lesions at an early transformation stage, thus enabling the early diagnosis of colorectal precancerous lesions. Furthermore, the methylation detection method and kit of the present invention enables colorectal precancerous lesions to be effectively diagnosed in an accurate and rapid manner compared to conventional methods.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: April 23, 2019
    Assignee: GENOMICTREE, INC.
    Inventors: Sungwhan An, Tae Jeong Oh
  • Patent number: 10261096
    Abstract: This invention relates to a method of diagnosing the depression, and more particularly to a method and kit for diagnosing depression after acute coronary syndrome, by measuring the concentration of a specific biomarker in the blood of a patient suffering from acute coronary syndrome to predict depression after acute coronary syndrome.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 16, 2019
    Inventors: Jae Min Kim, Hee Ju Kang
  • Patent number: 10260099
    Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: April 16, 2019
    Inventors: Antonio V. Delgado-Escueta, Kazuhiro Yamakawa, Toshimitsu Suzuki, Marco Tulio Medina-Hernandez, Maria Elisa Alonso Vilatela
  • Patent number: 10233497
    Abstract: Methods for determining the presence or absence of expansion of CGG repeat sequence in the FMR1 gene presence or absence of expansion of CCG repeat sequence in the FMR2 gene are provided. The methods are useful in identifying an individual with normal/intermediate, versus premutation or full mutation allele of FMR1 gene and FMR2 gene due to the expansion of CGG repeats and CCG repeats in the 5?-untranslated region respectively. The methods are also useful for screening newborns for fragile X syndrome or for screening women to determine heterozygosity status with full premutation of the CCG repeat tract. The methods are also useful in estimating the premutation and full mutation carrier frequency and estimating the prevalence of FXTAS AND FXPOI in a population. The methods are simple, rapid and require small amount of sample.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: March 19, 2019
    Assignee: Quest Diagnositcs Investments Incorporated
    Inventors: Feras Hantash, Weimin Sun, David C. Tsao, Dana Marie Root, Charles M Strom
  • Patent number: 10174382
    Abstract: A genetic biomarker panel is provided for prognosing late onset ER+ breast cancer relapse, in a breast cancer survivor patient. Kits are also provided for measuring levels or the presence of an identified panel of genetic biomarkers. Methods are also provided for identifying a breast cancer survivor patient at a relatively high risk of suffering a breast cancer relapse within 8 years of diagnosis, and therefore suitable for treatment with an aggressive chemotherapeutic regimen. The method may also be used for identifying a breast cancer survivor patient not at high risk of suffering a breast cancer relapse within 8 years of diagnosis, and thus not suitable for treatment with an aggressive chemotherapeutic regimen. The genetic biomarker panel includes an oligonucleotide/nucleic acid sequence specific for the following genes: MKI67, SPAG5, ESPL1, PLK1, or a genetic panel for MKI67, SPAG5, ESPL1, PLK1 and PGR.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: January 8, 2019
    Assignees: University of Notre Dame, Indiana University Research and Technology Corporation
    Inventors: Steven Buechler, Sunil Badve, Yesim Gokmen-Polar
  • Patent number: 10174378
    Abstract: The present invention is a tool for diagnosis and prediction using biomarker-based risk assessment for chilling-related disorders of Rosaceous fruit crops including apple and pear. Provided are methodology and genes whose relative and absolute expression can accurately indicate disorder risk throughout the production and supply chain of these crops. This technology describes a necessary and novel management tool for stakeholders producing, servicing, or retailing these crops.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: January 8, 2019
    Assignees: The United States of America, as represented by the Secretary of Agriculture, Cornell University, The New Zealand Institute for Plant and Food Research, Katholieke Universiteit
    Inventors: David R. Rudell, Jr., Rachel S. Leisso, James P. Mattheis, James J. Giovannoni, Nigel E. Gapper, Nicolai M. Bart, Chris B. Watkins, Jason W. Johnston, Maarten L. Hertog, Robert J. Schaffer
  • Patent number: 10167513
    Abstract: The invention provides compositions and methods for detecting a neoplasia (e.g., pancreatic cancer, lung cancer, colon cancer) in a subject sample (e.g., serum, blood, plasma, tissue). In particular embodiments, the invention provides methods for detecting BNC1 and ADAMTS1 promoter methylation in circulating DNA in serum.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: January 1, 2019
    Assignee: The Johns Hopkins University
    Inventors: Nita Ahuja, Stephen Baylin, James G. Herman, Jeff Wang, Vasudev Bailey, Mi J. Yi
  • Patent number: 10161006
    Abstract: The present invention relates to a method for screening a risk group of a hematologic disease and a method for analyzing the prognosis of a hematologic disease based on the measurement of the level of gelsolin mRNA in buffy coat of peripheral blood or a bone marrow aspirate. The use of the present invention enables the screening of a risk group of a hematologic disease and the analysis of prognosis of a patient with a hematologic disease in an easy and accurate manner.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: December 25, 2018
    Inventors: Eun Jung Baek, Eun-Mi Lee
  • Patent number: 10155987
    Abstract: This present invention provides methods of treating of assessing/monitoring the responsiveness of a cancer cell to JAK inhibitor therapy.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: December 18, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Martin Sattler, Anagha Deshpande, James D. Griffin
  • Patent number: 10150998
    Abstract: The present invention relates to a method of determining the susceptibility of a dog to, or the likelihood that a dog is protected from, hip dysplasia. The present invention uses mutations linked to canine hip dysplasia to generate a model predicting disease.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: December 11, 2018
    Inventor: Alan Martin
  • Patent number: 10150997
    Abstract: The present invention provides a method of testing a dog to determine the susceptibility of the dog to liver copper accumulation, comprising detecting in a sample the presence or absence in the genome of the dog of one or more polymorphisms selected from: (a) Chr22_3167534 (SEQ ID NO: 144), Chr22_3135144 (SEQ ID NO: 145), Chr20_55461150 (SEQ ID NO: 146), ChrX_120879711 (SEQ ID NO: 147), Chr19_6078084 (SEQ ID NO: 148), Chr15_62625262 (SEQ ID NO: 149), Chr14_39437543 (SEQ ID NO: 150), Chr15_62625024 (SEQ ID NO: 151), Chr3_86838677 (SEQ ID NO: 152), Chr24_4011833 (SEQ ID NO: 153), Chr18_60812198 (SEQ ID NO: 154), Chr10_65209946 (SEQ ID NO: 155), and the CGCCCC repeat at chromosome location 22:3135287; (b) one or more polymorphisms in linkage disequilibrium with a said polymorphism (a); and/or (c) Chr32_38904515 (SEQ ID NO: 156), Chr8_4892743 (SEQ ID NO: 157) and Chr8_4880518 (SEQ ID NO: 158).
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: December 11, 2018
    Inventors: Alan James Martin, Paul Glyn Jones, Adrian Watson, Jan Rothuizen, Hille Fieten, Pieter Antonius Jozef Leegwater
  • Patent number: 10144969
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: December 4, 2018
    Assignee: Colgate-Palmolive Company
    Inventor: Xiangming Gao
  • Patent number: 10147505
    Abstract: The present invention provides method of classifying a subject into a necrotizing meningoencephalitis (NME) disease risk group. The method may include assessing the presence of one or more marker (e.g., SNPs or risk loci) in a sample from the subject. For example, detection of the presence of one or more markers that are associated with an increased risk of NME can indicate that the subject should be classified into a risk group.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 4, 2018
    Assignees: The Translational Genomics Research Institute, University of Georgia Research Foundation, Inc.
    Inventors: Matthew Huentelman, Scott Schatzberg, Renee Barber
  • Patent number: 10138522
    Abstract: Provided herein are methods and compositions for determining the susceptibility of cattle to High Altitude Pulmonary Hypertension. Also provide are kits and reagents for performing such methods.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: November 27, 2018
    Inventors: John H. Newman, Rizwan Hamid, John A. Phillips, Joy Cogan, Timothy N. Holt
  • Patent number: 10138521
    Abstract: The present disclosure relates generally to the field of epigenetics and in particular epigenetic profiles associated with a pathological condition. The present specification teaches screening of individuals and populations for epigenetic profiles associated with a pathological condition. The epigenetic profiles can be from an intron, an intron/exon boundary or a splicing region. Epigenetic profiles are disclosed from the following sites in the FMR locus: FREE3, intron 2 of FMR1, the genomic FREE2 region as a whole or specific FREE2 fragments including FREE2 (D) or FREE2 (E). Kits and diagnostic assays are also taught herein as are computer programs to monitor changes in epigenetic patterns and profiles. Further enabled herein is a method for screening for agents which can reduce or mask the adverse effects of epigenetic modification and the use of these agents in therapy and prophylaxis.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: November 27, 2018
    Assignee: Murdoch Childrens Research Institute
    Inventor: David Eugeny Godler
  • Patent number: 10131950
    Abstract: Method and kits for diagnosing propensity to non-contact cranial cruciate ligament rupture (CCLR) in a dog are described. The method includes isolating genomic DNA from a dog and then analyzing the genomic DNA from step for a single nucleotide polymorphism occurring in selected loci that have been determined to be associated with the CCLR phenotype via a genome-wide association study.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: November 20, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Peter Muir, Lauren Baker
  • Patent number: 10125397
    Abstract: The disclosure includes methods of identifying a dog at risk of developing a an autoimmune disease or condition, for example a hypothyroid disease or condition, comprising testing whether the dog exhibits one or more selected single nucleotide polymorphisms (SNPs), together with diagnostic kits for carrying out such methods, methods of treatment or prophylaxis of such autoimmune disease or condition, e.g., comprising administering an effective amount of tea extract to a dog in need thereof, and a canine diet or supplement comprising tea extract, useful for treatment of prophylaxis of such autoimmune disease or condition, or for maintenance of thyroid health in a dog.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: November 13, 2018
    Inventors: Jeffrey Brockman, Matthew J. Huentelman
  • Patent number: 10106854
    Abstract: The present application concerns methods and tools for diagnosing prostate cancer and furthermore concerns methods and tools for prognosing disease progression of prostate cancer. The method comprises determining methylation level of the genes C1orf114, HAPLN3, AOX1, GAS6, ST6GALNAC3 and ZNF660 and comparing the result with a control, thus obtaining a response which is used for diagnosing a prostate cancer and/or for prognosing aspects of an individual suffering from prostate cancer.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: October 23, 2018
    Assignees: Aarhus Universitet, Region Midtjylland
    Inventors: Torben Falck Ørntoft, Karina Dalsgaard Sørensen, Christa Haldrup
  • Patent number: 10100370
    Abstract: The present invention features compositions and methods for detecting Huanglongbing (HLB) in citrus trees and insects. In one aspect, the invention provides a method of detecting a Huanglongbing (HLB) infection in a citrus grove involving obtaining an extract from a biological sample derived from a citrus grove, contacting the extract with forward and reverse primers that specifically bind a Candidutus nucleic acid molecule in the presence of a nicking enzyme, dNTPs, and a polymerase under conditions permissive for the isothermal amplification of the nucleic acid molecule; and detecting a Candidutus amplicon in the extract.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: October 16, 2018
    Assignee: ENVIROLOGIX INC.
    Inventors: Breck Parker, Susan Tapley, Paula Lampton